Return on Tangible Equity: The amount of net income returned as a percentage of shareholders equity, after subtracting intangible assets, goodwill and preferred equity. Calculated as: Income from Continuing Operations / Tangible Shareholders Equity
Inhibitor Therapeutics, Inc. (INTI) had Return on Tangible Equity of 23.99% for the most recently reported fiscal quarter, ending 2026-06-30.
| Income Statement Financials | |
-- |
|
$-0.61M |
|
-- |
|
-- |
|
$0.62M |
|
$-0.62M |
|
$0.00M |
|
$-0.61M |
|
$-0.61M |
|
$-0.61M |
|
$-0.61M |
|
$-0.61M |
|
$-0.61M |
|
$-0.62M |
|
$-0.62M |
|
173.31M |
|
173.31M |
|
$0.00 |
|
$0.00 |
|
| Balance Sheet Financials | |
$0.59M |
|
-- |
|
$0.05M |
|
$0.64M |
|
$0.17M |
|
-- |
|
$3.02M |
|
$3.20M |
|
$-2.56M |
|
$-2.56M |
|
$-2.56M |
|
173.79M |
|
| Cash Flow Statement Financials | |
$-1.86M |
|
-- |
|
-- |
|
$2.38M |
|
$0.52M |
|
$-1.86M |
|
$0.03M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
3.36 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-1.86M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
23.99% |
|
|
Return on Tangible Equity |
23.99% |
-96.35% |
|
23.99% |
|
$-0.01 |
|
$-0.01 |
|
$-0.01 |
|